

Perinatal tissue banking for ATMP development

Tomasz Baran, MD,MBA

Chief Medical Officer

FamiCord Group

FamiCord at a glance

- ✓ No. 1 in Europe, No. 3 worldwide
- ✓ 1,0 mln+ k biological samples stored

**Leading European
tissue & cell bank**



- ✓ Steady recurring cash flow generation
- ✓ Transparent and trusted activity –
 - Frankfurt Stock Exchange listed
(previously as Vita 34 AG)

- ✓ Drug Manufacturing & Related
 - Human CGT applications
 - Multiple CDMO contracts
 - Tech transfer & analytical services



**Cell and Gene
Therapies**




A FAMICORD COMPANY

BRAMBLE
BIO

- ✓ Released ATMP (HE or ATIMP)
 - Cord blood (brain disorders)
 - MSC based
 - DT- DEC001
 - CAR-T

FamiCord overview

- **# 1 in Europe & # 3 in the world**
- **~55% of market share in Europe**
- **> 1 million of samples stored**
 - cord blood ,cord tissue ,placenta
 - family, public and hybrid models
- **~ 8 000 patients treated**
- **15 labs (incl 2 just storage)**
- **2 CDMO GMP centers (PL, PT)**
 - 2 locations in Germany



FamiCord tissue establishments in Germany


LEIPZIG **ViTA34**

- Autologous and allogenic licenses
- Tissues banked:
 - Cord blood
 - Cord tissue
 - Placenta

ROSTOCK **Seracell** Living Responsibility


- Autologous and allogenic licenses
- Tissues banked:
 - Cord blood
 - Peripheral blood for transplant, DLI and CAR-T

The concept of cord blood banking 2.0.




Cord blood application is entering into the new fields of application –as ATMP

Page 8 of 21




CELL
THERAPY IN
CEREBRAL
PALSY
TREATMENT
OPTIONS

In line with GMP: from donor selection to clinical application



FamiCord manufacturing process has been mastered based on Mesenchymal Stem/Stromal Cells manufacturing,
Now implemented for other cell or gene therapy products,
including CART production

Over 10 years of cell products manufacturing for clinical trials



	Project	Cooperator	CT phase	Product description and cell source	Indication	Route of administration
	ProTrans (CDMO)	NextCell Pharma AB	1, 1/2 , 2	Product based on cells of selecting and pooling Wharton's Jelly-MSC donors	Diabetes T1 COVID-19	intravenous
						
	MSC-FIBRO (CDMO)	Medical University of Gdansk	1/2	Product based on cells of selecting Wharton's Jelly-MSC donors	Idiopathic pulmonary fibrosis	intravenous
	Dystrogen (CDMO)	Dystrogen Therapeutics	HE	Dystrophin Expressing Chimeric Cells (DEC) based products produced using on transferred technology developed by Dystrogen Therapeutics	Duchenne Muscular Dystrophy	into bone marrow
						
	ABC Therapy (CDMO)	Warsaw Medical University	1/2	Products based on autologus Adipose Tissue-MSC	Scars and cutis laxa syndrome	intravenous
	BIOOPA (CDMO)	Warsaw Medical University	1/2	Biodressing consisting of human decellularized skin covered with Wharton's Jelly-MSC	Epidermolysis Bullosa	epidermal
	ALSTEM	PBKM	1/2a	Products based on cells of Wharton's Jelly-MSC.	Amyotrophic lateral sclerosis	Intrathecal
	BIONCART (CDMO)	BIONCART & Fraunhofer IZI Leipzig	1/2a	Wharton's Jelly-MSC based intermediate product supplier	Osteoarthritis	into joint

Stem Cell Reviews and Reports
<https://doi.org/10.1007/s12015-020-10016-7>

Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study

Monika Barczewska^{1,2,3} • Stanisław Maksymowicz^{2,4}  • Izabela Zdolińska-Malinowska⁵ • Tomasz Siwek^{2,3,6} • Mariusz Grudniak⁵



Special Report

For reprint orders, please contact: reprints@futuremedicine.com



The use of mesenchymal stem cells for the treatment of progressive retinal diseases: a review

Agnieszka Borkowska-Kuczkowska^{1,2}, Dariusz Borucki³

¹Polish Center of Cell Therapy & Immunotherapy in Czes

²Agamed Center of Ophthalmology, Jasnogórska 4, 42-2

³Polski Bank Komórek Macierzystych SA (FamiCord Group)

*Author for correspondence: Tel.: +48 50 001 9940; don

Stem Cell Reviews and Reports
<https://doi.org/10.1007/s12015-024-10742-2>

The Impact of Umbilical Cord Mesenchymal Stem Cells on Motor Function in Children with Cerebral Palsy: Results of a Real-world, Compassionate use Study

Magdalena Chrościńska-Kawczyk¹ • Izabela Zdolińska-Malinowska²  • Dariusz Borucki²

Accepted: 27 May 2024

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024



Received: 19 January 2021 | Accepted: 16 June 2021
DOI: 10.1002/scrm.21-0027

HUMAN CLINICAL ARTICLE



The use of umbilical cord-derived mesenchymal stem cells in patients with muscular dystrophies: Results from compassionate use in real-life settings

Beata Świątkowska-Flis^{1,2} | Izabela Zdolińska-Malinowska³  | Dominika Sługocka¹  | Dariusz Borucki³

Hindawi
Stem Cells International
Volume 2019, Article ID 7402151, 13 pages
<https://doi.org/10.1155/2019/7402151>



Research Article

Wharton's Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study

Dariusz Borucki¹  and Izabela Zdolińska-Malinowska¹ 

Polski Bank Komórek Macierzystych S.A./FamiCord Group (Polish Stem Cell Bank), Jana Pawła II 29, Warsaw, Poland

Correspondence should be addressed to Dariusz Borucki; dariusz.borucki@pbkm.pl and Izabela Zdolińska-Malinowska; izabela.zdolinska-malinowska@pbkm.pl

Adv. Exp. Medicine, Biology - Neuroscience and Respiration
DOI 10.1007/5584_2017_9
© Springer International Publishing Switzerland 2017


Knee Cartilage Regeneration with Umbilical Cord Mesenchymal Stem Cells Embedded in Collagen Scaffold Using Dry Arthroscopy Technique

B. Sadlik, G. Jaroslawski, D. Gladysz, M. Puszkarz, M. Markowska, K. Pawelec, D. Borucki, and T. Oldak

More Than a Stem Cell Bank

FamiCord unparalleled track record of releases for therapy

Patients received SC from different SC sources	Cord Blood *			Cord Tissue			Bone marrow or mobilised peripheral blood	Adipose tissue			DT-DEC01
PROCEDURE DATE	Since 2004			Since 2011			Since 2007	Since 2018			Since 2021
TYPE OF THERAPY	Experimental	Standard	ATMP-HE**	Not ATMP	ATMP-HE**	Clinical Trial	Standard	Not ATMP	ATMP-HE**	Clinical Trial	ATMP-HE**
AUTOLOGOUS	104	10	22	4	0	0	1204	5	43	66	0
ALLOGENEIC	4	11	0	1	0	0	4770	0	0	0	0
ALLOGENEIC - RELATED	17	98	0	22	157	0	0	0	0	0	8
ALLOGENEIC - UNRELATED	1	3	0	10	1725	80	0	0	0	0	0
ALLOGENEIC - RELATED&UNRELATED	0	0	0	0	6	0	0	0	0	0	0
Total per product type	126	122	22	37	1888	80	5974	5	43	66	8
	270			2005				114			
TOTAL PATIENTS	8372										



Status as of March 2026



Thank You

tomasz.baran@famicord.com

